Panacea Biotec Ltd

  • BSE Code : 531349
  • NSE Symbol : PANACEABIO
  • ISIN : INE922B01023
  • Industry :PHARMACEUTICALS - INDIAN - BULK DRUGS & FORMLN

up-arrow 323.40 -1.90(-0.58%)

Open Price ()

327.00

Prev. Close ()

325.30

Volume (No’s)

60,123

Market Cap ()

1,980.85

Low Price ()

315.00

High Price ()

327.00

 

Book Closure

From Date To Date Announcement
30-Jun-2026 NA We would like to inform you that CA Rajesh Jain, Independent Director of the Company and its material wholly owned subsidiary, Panacea Biotec Pharma Limited ('PBPL') vide his e-mails dated 30.03.2026, has tendered the resignation as Independent Director of the Company and PBPL w.e.f. close of business hours on 30.06.2026. A detailed disclosure to be disclosed under SEBI LODR Regulations read with SEBI Master Circular dated 11.11.2024 are enclosed herewith.
31-Mar-2026 NA We would like to inform you that Mr. Mukul Gupta (DIN: 00254597) Independent Director of the Company has completed his second and final term of 5 consecutive years as Independent Director on 31.03.2026 and accordingly he has ceased to be an Independent Director of the Company. A detailed disclosure as required under Regulation 30 of SEBI LODR Regulations read with SEBI Master Circular dated 30.01.2026 is annexed herewith.
11-Feb-2026 NA Panacea Biotec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 ,inter alia, to consider and approve Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and nine months ended December 31, 2025. The trading window of the Company shall remain closed for all Designated Persons (including their Immediate relatives) of the Company till February 13, 2026. We would like to inform you that the Board of Directors has in its meeting held today i.e. 11.02.2026, inter-alia considered and approved the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31.12.2025. The same was also reviewed by the Audit Committee in its meeting held today. A copy of the said financial results along with Limited Review Report is enclosed herewith. (As per BSE announcement dated on : 11.02.2026)
16-Dec-2025 NA Mr. Vinod Goel (who is currently acting as Group CFO and Head Legal & Company Secretary as well as Compliance Officer of the Company) has been appointed as Chief Financial Officer under the category of KMP and SMP, designated as Group Chief Financial Officer and Head Legal & Corporate Governance of the Company, with effect from December 16, 2025, based on the recommendation and approval of the Nomination & Remuneration Committee and Audit Committee.
15-Dec-2025 NA We would like to inform you that Mr. Devender Gupta, Chief Financial Officer and Head Information Technology designated as Key Managerial Personnel and Senior Management Personnel of the Company has tendered his resignation on account of personal reasons w.e.f. December 15, 2025. The required disclosure in this regard is attached herewith. Mr. Vinod Goel (who is currently acting as Group CFO and Head Legal & Company Secretary as well as Compliance Officer of the Company) has been appointed as Chief Financial Officer under the category of KMP and SMP, designated as Group Chief Financial Officer and Head Legal & Corporate Governance of the Company, with effect from December 16, 2025, based on the recommendation and approval of the Nomination & Remuneration Committee and Audit Committee. (As Per BSE Announcement Dated on:15.12.2025)

Copyright © 2026 Arihant Capital Markets Ltd. All rights Reserved.

Designed, Developed and Content powered by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)

x
  • QR-CodeNew